Absci Corp Market Cap ($1.41 Billion)
Market Cap & Net Worth: Absci Corp (ABSI)
Absci Corp market cap. Absci Corp (NASDAQ:ABSI) has a market capitalization of $1.41 Billion ($1.41 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7188 globally and #2227 in its home market, demonstrating a 18.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Absci Corp's stock price $11.13 by its total outstanding shares 171614010 (171.61 Million). Also see ABSI cash generation efficiency for how efficiently the company converts equity into cash flow.
Absci Corp Market Cap History (2021–2026)
Absci Corp market cap history from 2021 to 2026. Data shows change from $1.41 Billion to $1.91 Billion (-11.80% CAGR). Check Absci Corp stock price for real-time trading data and today's change.
Index Memberships
Absci Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.05% | #212 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #811 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.08% | #125 of 263 |
Weight: Absci Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Absci Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Absci Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Absci Corp to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
213.90x
Absci Corp's market cap is 213.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.41 Billion | $4.78 Million | -$100.96 Million | 294.28x | N/A |
| 2022 | $360.39 Million | $5.75 Million | -$104.90 Million | 62.71x | N/A |
| 2023 | $720.78 Million | $5.72 Million | -$110.57 Million | 126.05x | N/A |
| 2024 | $449.63 Million | $4.53 Million | -$103.11 Million | 99.17x | N/A |
| 2025 | $598.93 Million | $2.80 Million | -$115.18 Million | 213.90x | N/A |
Competitor Companies of ABSI by Market Capitalization
Companies near Absci Corp in the global market cap rankings as of November 1, 2026. Also see Absci Corp balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Absci Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Absci Corp (2021–2026)
Market capitalization of Absci Corp from 2021 to today. Between 2021 and today, Absci Corp's market cap moved from $1.41 Billion to $ 1.91 Billion, with a yearly change of -11.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.91 Billion | +218.91% |
| 2025 | $598.93 Million | +33.21% |
| 2024 | $449.63 Million | -37.62% |
| 2023 | $720.78 Million | +100.00% |
| 2022 | $360.39 Million | -74.39% |
| 2021 | $1.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Absci Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.41 Billion USD |
| MoneyControl | $1.41 Billion USD |
| MarketWatch | $1.41 Billion USD |
| marketcap.company | $1.41 Billion USD |
| Reuters | $1.41 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more